In Vivo Cell Engineering Reaches an Inflection Point as the 5th In Vivo Cell Engineering & Gene Editing Summit Returns to Boston

The 5th In Vivo Cell Engineering & Gene Editing Summit returns to Boston this July, bringing together the scientific, translational, regulatory, and corporate leaders driving one of the fastest-accelerating fields in cell and gene therapy.

Following more than $7.3 billion in in vivo focused acquisitions over the past year, a wave of first-in-human signals and significant advances in extrahepatic delivery, the 2026 meeting arrives as the field enters a defining period of clinical maturation and commercial positioning.

A Pivotal Year for In Vivo Approaches

In vivo strategies are rapidly moving beyond their historical focus on hepatic targets. Companies across the US, Europe, and Asia are expanding into autoimmune disease, solid tumors, and tissue-specific indications, enabled by improvements in targeting specificity, next-generation LNP and viral designs, and more sophisticated translational modeling. Speakers from Intellia Therapeutics, Kite Pharma, Sana Biotechnology, GigaMune, Beam Therapeutics, CREATE Medicines, and many others will share cross-disciplinary insights that reflect a field preparing for global scale.

“The rapid growth in the field means that the 5th In Vivo Cell Engineering & Gene Editing Summit is now one of the most important events to hear from the leaders in the space where this field is and where it is going,” notes Stefanos Theoharis, CEO of OneChain Immunotherapeutics and 2026 speaker.

A Comprehensive Agenda Reflecting Clinical Progress and Modality Innovation

Across three days, attendees will gain access to the most advanced thinking in in vivo delivery, editing, and regulatory strategy.

Key sessions include:

• Targeted mRNA LNP Platforms for Autoimmunity:
  Innorna will present non-human primate data showing robust B-cell depletion and immune reset biology using targeted LNPs.
• In Vivo TRAC CAR-T Generation:
  Azalea Therapeutics will share information on enveloped delivery systems enabling precise, site-specific genomic integration for potent and tolerable TRAC CAR-T cells.
• Evolving Gene Editing Strategies:
  CorriXR Therapeutics, Velvet Therapeutics, and Verve Therapeutics will examine differentiated lentiviral systems, oncology-focused editing approaches, and durability-oriented base editing designs.
• Translational and Clinical Decision Making:
  iECURE will provide updates on adaptive cohort design, biomarker-guided dosing, and early patient readouts, shaping the next phase clinical strategy.

See the full program here: https://ter.li/qiwk13

New for 2026: Global Expansion and Strategic Connectivity

A dedicated “Spotlight on In Vivo Development in Asia” will outline how China’s regulatory ecosystem and regional pathways are accelerating first-in-human timelines and enabling global sponsors to responsibly integrate Asian clinical evidence.

This year also introduces the In Vivo Partnerships Networking Mixer, designed to connect biotechs, platform developers, and pharma teams seeking complementary capabilities in delivery, editing, CMC, and clinical translation.

Building the Future of In Vivo Therapies Together

Workshops on extrahepatic delivery and global clinical development strategies will provide hands-on frameworks for navigating biodistribution challenges, species differences, regulatory expectations, and modality-specific CMC planning.

Reflecting on the field’s trajectory, Eric Kmiec, Founder and CSO of CorriXR Therapeutics, says: “The field is maturing rapidly. What was once thought impossible is quickly becoming foundational. This summit continues to highlight the most innovative and practical paths forward.”

Registration is now open for developers, investors, translational scientists and partners shaping the next generation of in vivo therapies.

Learn more at https://ter.li/7bsc01